Lala Anuradha, Levin Adeera, Khunti Kamlesh
Department of Population Health Science, Icahn School of Medicine, New York, New York, USA.
Division of Nephrology, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Diabetes Obes Metab. 2025 Jul;27(7):3568-3582. doi: 10.1111/dom.16371. Epub 2025 Apr 21.
Chronic kidney disease (CKD) and heart failure (HF) are two globally prevalent, independent, long-term conditions, which often coexist in an individual and display a bidirectional yet interconnected relationship. The presence of CKD often leads to the development of HF and vice versa, which propagates the worsening of each disease, reflecting an intertwined disease cycle. Both HF and CKD share common risk factors, such as increasing age, diabetes, high blood pressure, obesity and smoking. Data show that approximately half of all people with HF also have CKD, which impacts patient burden and quality of life due to a significantly greater risk of hospitalization and death, compared with those that have either CKD or HF. To maximize treatment effectiveness in individuals with both HF and CKD, healthcare professionals should recognize that these two diseases are systemic conditions, representing organ-specific manifestations of similar underlying processes. It is also essential to understand the role of renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, the nonsteroidal mineralocorticoid receptor antagonist finerenone, and glucagon-like peptide-1 receptor agonists in managing these conditions. Lifestyle modifications should also be recommended. This review discusses factors contributing to the interplay between HF and CKD and the key role of healthcare professionals in providing appropriate treatment for the co-existing diseases.
慢性肾脏病(CKD)和心力衰竭(HF)是两种全球普遍存在的、独立的长期病症,它们常常在个体中共存,并呈现出双向但相互关联的关系。CKD的存在往往会导致HF的发生,反之亦然,这会促使每种疾病恶化,反映出一个相互交织的疾病循环。HF和CKD具有共同的风险因素,如年龄增长、糖尿病、高血压、肥胖和吸烟。数据显示,所有HF患者中约有一半也患有CKD,与单纯患有CKD或HF的患者相比,这会因住院和死亡风险显著增加而影响患者负担和生活质量。为了使同时患有HF和CKD的个体的治疗效果最大化,医疗保健专业人员应认识到这两种疾病是全身性疾病,代表了相似潜在过程的器官特异性表现。了解肾素 - 血管紧张素系统抑制剂、钠 - 葡萄糖协同转运蛋白2抑制剂、非甾体类盐皮质激素受体拮抗剂非奈利酮以及胰高血糖素样肽 -1受体激动剂在管理这些病症中的作用也至关重要。还应推荐生活方式的改变。本综述讨论了导致HF和CKD相互作用的因素以及医疗保健专业人员在为并存疾病提供适当治疗方面的关键作用。